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Abstract
The purpose of this study was to determine the effectiveness of Lactobacillus-containing vaginal tablets in the treatment of bacterial vagi-
nosis (BV) and in the restoration of a healthy vaginal ﬂora. Thirty-nine women with BV were enrolled in a double-blind, placebo-con-
trolled clinical trial. Patients received either one Lactobacillus-containing tablet or placebo daily for 7 days. Clinical criteria, vaginal Gram
stain scores and symptoms were compared with those at the initial visit and those at completion of therapy and 2 weeks later. After
completion of therapy, all of the patients in the Lactobacillus-treated group (n = 18) were free of BV, showing a normal (83%) or inter-
mediate (17%) vaginal ﬂora, as compared with only two patients free of BV with intermediate ﬂora (12%) from among the 16 placebo-
treated women (p <0.001). Two weeks after completion of therapy, treatment was successful (score <7) in 61% of Lactobacillus-treated
patients as compared with 19% of those in the placebo group (p <0.05). In the treatment group, the total number of symptomatic
patients and the intensity of their symptoms, in particular vaginal malodour, were signiﬁcantly reduced at both follow-up visits. The data
indicate that intravaginal administration of exogenous selected strains of lactobacilli can restore a normal vaginal microbiota and be used
in treating bacterial vaginosis.
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Introduction
Bacterial vaginosis (BV) is the most common vaginal disorder
among women of reproductive age, with a prevalence of 10–
29% in the entire female population [1,2]. BV is not caused
by one speciﬁc pathogenic microorganism, but rather by an
imbalance of vaginal microbial ﬂora, as well as, possibly,
other, still unknown, cofactors. In the presence of BV, the
lactobacilli, which represent the predominant microorgan-
isms in the healthy human vagina, are reduced, absent or
lacking speciﬁc antimicrobial properties (i.e. production of
H2O2). These are replaced by Gardnerella vaginalis and other
anaerobic organisms, e.g. Atopobium vaginae, Bacteroides,
Mobiluncus, Prevotella, Peptostreptococcus spp., Ureaplasma
urealyticum and Mycoplasma hominis, most of which are nor-
mally found in small amounts in the vagina [3]. Lactobacilli,
particularly those producing H2O2, play a pivotal role in con-
trolling the microenvironment of the vagina and in inhibiting
the overgrowth of potentially pathogenic organisms [4]. Pos-
sible mechanisms of this protection include inactivation of
pathogens by different Lactobacillus products (lactic acid,
H2O2 and bacteriocins), competition for epithelial cell attach-
ment sites and stimulation of the local immune system [5–7].
Women with BV typically complain of vaginal discomfort and
clinical symptoms such as homogeneous malodorous vaginal
discharge, which is more noticeable after unprotected inter-
course, although a substantial fraction of women are asymp-
tomatic [8]. The ‘ﬁshy’ odour, characteristic of vaginal
discharges in BV-affected women, is linked to the high levels
of polyamines produced by the abnormally growing anaero-
bic microorganisms [9,10]. Amines do indeed volatilize in an
alkaline environment, giving rise to the malodour [11,12].
Alterations in the vaginal microbiology, such as those
occurring in BV, have been associated with ascending infec-
tions and obstetrical complications [13], as well as with
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urinary tract infections [14,15]. A signiﬁcant association
between the depletion of vaginal lactobacilli and an increased
risk of prevalent and incident human papillomavirus infection
has been recently reported [16]. Increasing data also indicate
that BV facilitates the acquisition of sexually transmitted dis-
eases such as human immunodeﬁciency virus (HIV), herpes
simplex virus type 2, Neisseria gonorrhoeae and Chlamydia tra-
chomatis infection [17–20]. Moreover genital tract shedding
of herpes simplex virus type 2 and cytomegalovirus is signiﬁ-
cantly higher in women affected by BV than in BV-free
women, and female genital tract HIV load correlates inver-
sely with Lactobacillus count [19,21,22].
Therapy of BV involves oral or local administration of
metronidazole or intravaginal clindamycin, and varies in efﬁ-
cacy (48–85% [13] for absence of infection 4 or more weeks
after treatment).
There are several unpleasant side effects and disadvantages
associated with these therapies, including superinfections with
pathogenic microorganisms, susceptibility of lactobacilli to
clindamycin and high relapse rates [13,23,24]. Moreover, vagi-
nal pathogens, particularly G. vaginalis and anaerobic bacteria,
are showing increasing drug resistance [25,26].
The use of lactobacilli to re-establish a physiological
microbial ﬂora of the female urogenital tract dates back to
the early 1900s (reviewed by Sieber and Dietz [27]).
Renewed attention has recently been focused on approaches
involving alternative ‘natural’ treatments that could be effec-
tive in the microbiological and clinical resolution of the con-
dition without side effects. As recently reviewed by Falagas
et al. [28], several attempts have been made in recent years
to treat BV with Lactobacillus-containing products, with con-
ﬂicting results [29–33].
Vaginal tablets containing a combination of three strains of
lactobacilli (Lactobacillus brevis (CD2), Lactobacillus salivarius
(FV2) and Lactobacillus plantarum (FV9), characterized and
selected for the prophylaxis and treatment of vaginal infec-
tions, have been recently developed [34,35]. L. salivarius and
L. plantarum strains produce anti-infective agents, including
hydrogen peroxide, and are able to co-aggregate efﬁciently
with vaginal pathogens [35]. Co-aggregation produces a
microenvironment around the pathogen where the concen-
tration of inhibitors is increased. L. plantarum and L. brevis
strains are able to adhere at high levels to human epithelial
cells, displacing vaginal pathogens [35]. All the strains were
able to temporarily colonize the human vagina after 5 days
of treatment [36]. The present randomized, placebo-con-
trolled trial was designed to test the effectiveness of these
vaginal tablets for the treatment of BV and their ability to
restore physiological conditions in the vaginal environment
by re-establishing a normal, healthy ﬂora.
Materials and Methods
Patients
Women with a known history of recurrent bacterial vaginosis
were screened for the study. Bacterial vaginosis was deﬁned
according to Amsel et al. [37] by the presence of at least three
of the following criteria: (i) thin, homogeneous vaginal dis-
charge; (ii) vaginal pH higher than 4.5; (iii) ‘ﬁshy’ odour of vagi-
nal ﬂuid after addition of 10% KOH (whiff test); and (iv)
presence of clue cells on microscopic evaluation of saline wet
preparations. The patients were selected by gynaecologists of
the local gynaecological services from among women attending
the day clinic for recurrent bacterial vaginosis between
December 2002 and May 2004. Eligible subjects were preme-
nopausal women older than 18 years who fulﬁlled three or
more of the Amsel criteria for clinical diagnosis of BV and who
complained of vaginal symptoms and signs such as discharge
and ⁄or malodour. Exclusion criteria were pregnancy, diabetes,
the use of antibiotics or vaginal antimicrobials in the previous
14 days, Trichomonas vaginalis infection, yeast infection or cul-
tures positive for N. gonorrhoeae.
The study was conducted in accordance with the Declara-
tion of Helsinki and current standards of good clinical prac-
tice, and was approved by a review committee responsible
for ensuring the rights and safety of the research subjects.
Written informed consent was obtained from the patients.
Study medication
The test preparation consisted of vaginal tablets (Florisia;
VSL Pharmaceuticals, Inc., Towson, MD, USA,) containing at
least 109 viable lactobacilli (L. brevis (CD2), L. salivarius subsp.
salicinius (FV2), and L. plantarum (FV9)). The number of viable
Lactobacillus cells was veriﬁed every 6 months after prepara-
tion of vaginal tablets as previously described [34]. The pla-
cebo preparation did not contain lactobacilli, but contained
the same excipients as the test preparation, as described
by Maggi et al. [34], for fast-release formulation of vaginal
tablets. Treatment consisted of one Lactobacillus tablet daily
at bedtime for 7 days. Therapy was initiated after the enrol-
ment visit or immediately after the end of menstruation if
menses were expected within a 7-day period. Patients were
asked to avoid sexual intercourse and vaginal douching dur-
ing treatment.
Study design
This was a randomized, double-blind, placebo-controlled
study. Patients were assigned to therapy with active or pla-
cebo preparation according to a computer-generated rando-
mization scheme.
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None of the staff or patients had access to the randomiza-
tion codes during the study. The medications were dispensed
by the investigator at the initial visit; compliance was
assessed by counting returned tablets and questioning the
patients.
Evaluation and scheduling
Demographics and medical history concerning previous con-
traception, infectious disease history, sexual activity and his-
tory and last menstrual period were assessed at baseline.
Pelvic examination, assessment of clinical signs and symptoms
of vaginosis (vaginal discharge, unpleasant odour and subjec-
tive vulvar discomfort, graded according to a score: 0,
absence; +1, low; +2, intermediate; +3, high) and microbiolo-
gical ⁄ biochemical sampling were performed at baseline, and
after 1 and 3 weeks from the beginning of therapy.
Patients were assessed for BV according to the Amsel cri-
teria [37] and the Gram stain score of vaginal smears
according to Nugent et al. [38] The categories used to quan-
tify bacterial morphotypes in vaginal smears were 1+ (<1 cell
per ﬁeld), 2+ (1–4 cells per ﬁeld), 3+ (5–30 cells per ﬁeld)
and 4+ (>30 cells per ﬁeld). Two deﬁnitions of resolution
were considered: a Gram stain score of <7 (i.e. not BV) and
a Gram stain score of <4 (i.e. reversion to ‘normal ﬂora’)
with negativization of Amsel criteria.
At each follow-up visit, patients were requested to report
any unexpected symptom during the study period. Adverse
events were recorded in the case report form.
Specimen collection
Specimens were obtained from the lateral vaginal wall and
the posterior vaginal fornix with a cotton-tipped swab, and
then rolled over a glass slide for Gram stain analysis. The pH
of the vaginal contents was measured with indicator strips
(range 0–6, Merck). A second swab loaded with vaginal dis-
charge was placed in a sterile tube containing 0.5 mL of phy-
siological solution for amine test and identiﬁcation of clue
cells. Specimens for culture were placed in Amies transport
medium (Tansystem Venturi, Copan) and delivered to the
laboratory. Vaginal rinsing for polyamine analysis was per-
formed with 2 mL of 0.9% NaCl by ﬂushing and re-aspirating
the ﬂuid three times on vaginal walls.
Microbiological analysis
For the culture, vaginal swabs were inoculated on G. vaginalis
selective medium agar plates (Oxoid, SpA, Milan, Italy) and
HHD agar plates (Biolife, Italiana Srl, Milan, Italy) for lactoba-
cilli isolation. The plates were incubated under micro-aero-
philic conditions for 48 h at 37C. The cultures on
G. vaginalis selective medium were checked for colony mor-
phology, and Gram stain and catalase test were performed
for presumptive identiﬁcation of G. vaginalis. The strains were
identiﬁed at species level with the API 20 Strep system (bio-
Me´rieux Italy) and by testing susceptibility to metronidazole
and sulphonamide. Colonies grown on HHD agar were ana-
lysed for morphology, for homofermentative and heterofer-
mentative characteristics and for cell morphology after Gram
stain. Final conﬁrmation was based on the carbohydrate fer-
mentation proﬁle determined with API 50 CHL test strips
(bioMe´rieux Italy).
Polyamine analysis
The vaginal ﬂuid lavages were prepared according to Fu et al.
[39]. Two millilitres of vaginal washings was lyophilized and
then redissolved in 300 lL of 0.05 M phosphate buffer
(pH 7.0). To remove proteins, 150 lL of trichloroacetic acid
(30%) was added. The supernatant was neutralized with satu-
rated sodium carbonate and derivatized with dansyl chloride.
For derivatization, the reactant solution consisted of 200 lL
of dansyl chloride dissolved in acetone (10 mg ⁄mL), 400 lL
of neutralized sample supernatant, 50 lL of 140 lM hexam-
ethylendiamine and 50 lL of saturated sodium carbonate.
The mixture was incubated in a water bath for 10 min at
70C. One hundred microlitres of this solution was analysed
by HPLC. HPLC analysis was performed with a Waters-Milli-
pore apparatus (Milford, MA, USA). Samples were applied to
a reverse-phase column (Symmetry C18, 5 lm,
4.6 · 250 mm). The chromatography was carried out in gra-
dient conditions at 50C in a thermostatic apparatus, using a
one-step-linear gradient from 80% to 100% of methanol in
20 min, with a ﬂow rate of 1 mL ⁄min. Detection was carried
out using a ﬂuorescence detector (kex = 370 nm,
kem = 506 nm). Peak quantitation was performed by auto-
matic peak area integration using dedicated software (Millen-
nium 32, Waters). Results were expressed as nanomoles per
millilitre of vaginal washing.
Statistical analysis
The statistical analysis was performed using SPSS 13.0 soft-
ware. The Mann–Whitney U-test was used to compare dif-
ferences between the two treatment groups. A p-value of
less than 0.05 was considered to be statistically signiﬁcant.
Results
Study population
Forty-nine patients were screened, 39 of whom were eligible
and participated in this trial. Twenty patients were randomly
assigned to receive the test preparation and 19 to receive
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placebo. Ten patients were excluded; four of them refused to
give consent and six did not meet the inclusion criteria. Five
patients dropped out of the study (one patient required anti-
biotic therapy and four did not return for the follow-up vis-
its), leaving 34 evaluable patients (active treatment, n = 18;
placebo, n = 16). The baseline characteristics of women ran-
domly assigned to the test preparation or placebo were
demographically similar (Table 1). Gram stain scores of vagi-
nal smears did not signiﬁcantly differ by treatment group. All
of the women with BV diagnosed according to the clinical cri-
teria of Amsel had vaginal Gram stains that were either inter-
mediate (9%) or consistent with bacterial vaginosis (91%). At
the time of inclusion, the majority of patients (31 ⁄ 34) showed
an absence of or very low amounts of lactobacilli in the vagi-
nal ﬂuid, as assessed by culture and Gram-stained smear eva-
luation. At that time, only three women with intermediate
ﬂora had more than ﬁve lactobacilli per high-power ﬁeld in
vaginal samples. Vaginal ﬂuids from these patients had a pH
value of 4.5. All but two patients (one in each group) had the
maximum score for Gardnerella morphotypes, with seven
women also showing presence of Mobiluncus.
Seven-day assessment
At the ﬁrst follow-up visit (Table 2), all of the patients in the
Lactobacillus-treated group were free of BV, showing a nor-
mal (83%) or intermediate (17%) vaginal ﬂora. All of the
women had lactobacilli in vaginal samples, as assessed by cul-
ture and Gram-stained smear evaluation. Of the 16 women
presenting with an absence of or a very low amount of lacto-
bacilli at inclusion, 12 (75%) showed a very good colonization
after probiotic administration (11 patients, 4+; one patient,
3+), two showed intermediate colonization (2+), and two
remained unchanged (fewer than one lactobacillus per high-
power ﬁeld). Interestingly, in the two women with an initially
high Lactobacillus count (intermediate ﬂora), the amount of
lactobacilli decreased to lower values (2+). The score of
Gardnerella morphotypes also decreased from the maximum
(4+) to intermediate and low values in these patients. Thus,
one of these patients returned to normal and one retained
the same Gram stain score. In the actively treated group all
of the women showed a strong reduction in the number of
Gardnerella morphotypes that were absent, or present in
very low amounts, in ten women (56%), whereas seven
patients (39%) had intermediate colonization (2+) (data not
shown). None of the patients in the placebo group recov-
ered, although one woman with initial BV shifted to inter-
mediate ﬂora. The patient with intermediate ﬂora at the
initial visit retained the same Gram stain score. No variation
in the number of lactobacilli was observed among controls in
comparison to that at enrolment; lactobacilli were absent in
12 subjects (75%) or present at very low concentrations.
G. vaginalis was isolated from the vaginal ﬂuid of two and 13
women from the Lactobacillus-treated group and the placebo-
treated group, respectively.
Twenty-one-day assessment
By the second follow-up visit, Nugent Gram stain of vaginal
smears was signiﬁcantly different between the Lactobacillus-
treated group and the placebo-treated group (p 0.017).





(n = 16) p-value
Age (years, mean ± SD) 33 ± 9.9 35 ± 9.2 0.54
Nugent Gram stain score 0.62
Score 4–6 2 (11%) 1 (6%)
Score 7–10 16 (89%) 15 (94%)
Mean Gram stain score ± SD 7.4 ± 1.3 7.7 ± 0.9 0.37
Amsel criteria
pH >4.5 16 (89%) 15 (94%) 0.61
Positive amine odour 17 (94%) 14 (87%) 0.47
Clue cells present 18 (100%) 15 (94%) 0.28
Thin homogeneous discharge 18 (100%) 16 (100%) NA
Mean no. of positive Amsel criteria 3.83 3.75 0.46
Positive culture for Gardnerella vaginalis 14 (78%) 14 (87%) 0.46
Lactobacilli ⁄ ﬁeld 0.72
5+ (score 0–1) 2 (11%) 1 (6%)
>0–4 (score 2–3) 6 (33%) 4 (25%)
0 (score 4) 10 (56%) 11 (69%)
SD, standard deviation; NA, not applicable.





No. % No. %
First follow-up
Normalization of Amsel criteria 15 83 1 6
Nugent Gram stain scorea
Normal (0–3) 15 83 0 0
Intermediate (4–6) 3 17 2 12
Bacterial vaginosis (7–10) 0 0 14 88
Mean Gram stain score ± SD 2 ± 1.9 7.6 ± 1.1
Lactobacilli ⁄ ﬁelda
5+ (score 0–1) 12 67 0 0
>0–4 (score 2–3) 6 33 4 25
0 (score 4) 0 0 12 75
Positive culture for Gardnerella
vaginalis
2 11 13 81
Second follow-up
Normalization of Amsel criteria 12 67 2 12
Nugent Gram stain scoreb
Normal (0–3) 9 50 1 6
Intermediate (4–6) 2 11 2 12
Bacterial vaginosis (7–10) 7 39 13 81
Mean Gram stain score ± SD 4.3 ± 3.3 7.4 ± 1.5
Lactobacilli ⁄ ﬁeldc
5+ (score 0–1) 8 44 1 6
>0–4 (score 2–3) 6 33 2 12
0 (score 4) 4 22 13 81
Positive culture for G. vaginalis 7 39 13 81
a <0.001 for comparison between Lactobacillus-treated and placebo-treated
groups.
bp 0.017 and cp 0.02 for comparison between Lactobacillus-treated and placebo-
treated groups.
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Treatment was successful (score <7 and normalization of
Amsel criteria) in 11 of the Lactobacillus-treated patients
(61%) as compared with three (19%) of the placebo group.
Nine patients (50%) among the actively treated women had
normal vaginal smear results (score <4) in comparison to
one (6%) in the control group. In the treatment group, both
women with a high number of lactobacilli at entry (inter-
mediate ﬂora) showed a return to normal ﬂora. The Gram
stain Lactobacillus score was signiﬁcantly higher in patients
treated with lactobacilli in comparison with the placebo
group (p 0.02). Microbiological analysis demonstrated that
14 ⁄ 18 (78%) women treated with Lactobacillus-containing
vaginal tablets harboured lactobacilli in vaginal ﬂuid. In eight
of these patients, lactobacilli were present at very high levels,
whereas six had lower amounts of lactobacilli. Gardnerella
and Bacteroides spp. morphotypes were absent, or present in
small amounts, in women recolonized with lactobacilli, but
were found at high levels in non-recolonized patients.
The tablets caused no detectable side effects, and good
compliance was observed in all the patients.
Effect of treatment on symptoms
The symptoms of patients before and after treatment are
reported in Table 3. A signiﬁcant reduction in the number of
patients with symptoms and clinical signs at both follow-up
visits, in comparison to the number with symptoms and clini-
cal signs at the enrolment visit, was observed in the treat-
ment group (p <0.05). Moreover, all of the still-symptomatic
women, upon further examination, showed a reduction in
the score of symptoms. Increased vaginal discharge and sub-
jective vulvar discomfort disappeared at the ﬁrst follow-up
visit in 56% (10 ⁄ 18) and 71% (10 ⁄ 14), respectively, of the
women who received Lactobacillus-containing tablets, in com-
parison with none and 25% (3 ⁄ 12), respectively, of the pla-
cebo recipients. Similar ﬁndings were observed at the
second follow-up visit. At the control endpoint, malodorous
vaginal discharge was signiﬁcantly reduced in most of the
actively treated patients. Sixteen of 17 patients reported
improvement by one to three gradations. The median odour
score of all patients was 2.5 at the inclusion visit and 0 at
the two follow-up visits. Overall, 71% (12 ⁄ 17) of patients,
including three women still affected by BV, showed complete
resolution of vaginal malodour, in comparison with 12%
(2 ⁄ 16) of the placebo group. The median odour score of
symptomatic patients decreased from 3 to 1.5 and 3 to 1,
respectively, at the two follow-up visits.
Vaginal secretions of a subset of patients (ﬁve in the active
treatment group and three in the placebo group) were ana-
lysed for the presence of and the amount of polyamines, e.g.
putrescine and cadaverine, before and after treatment. The
mean concentrations of putrescine and cadaverine in the
secretions from three actively treated women who recov-
ered shifted from 149 ± 28 and 321 ± 70 nmol ⁄mL to
6 ± 3.6 and 1.1 ± 1 nmol ⁄mL, respectively, and 5.7 ± 1.9 and
2.3 ± 2 nmol ⁄mL, respectively, at the two follow-up visits. A
representative HPLC proﬁle of polyamines in vaginal samples
from a patient treated with the probiotic preparation is
shown in Fig. 1. Putrescine and cadaverine, which were
found in high concentrations at inclusion (Nugent score 7),
were drastically reduced at the two follow-up visits (Nugent
score 0 and 3, respectively). The amine concentration in ﬁve
women with persistent BV (two in the treatment group and
three in the placebo group) did not show signiﬁcant changes.
Discussion
The current study demonstrates the effectiveness of vaginal
tablets containing selected strains of lactobacilli in the resolu-
tion of BV. At the ﬁrst follow-up, all patients were free of
BV, presenting with a normal (83%) or intermediate (17%)
vaginal ﬂora. Treatment with the probiotic preparation was
61% effective in eliminating BV and 50% effective in restoring
‘normal vaginal ﬂora’ as determined by Gram stain at the
ﬁnal follow-up. The statistical analysis demonstrates a signiﬁ-
cant difference between the actively treated and the placebo
groups; however, as ﬁve participants dropped out of the
study, the effect of attrition bias should not be excluded. Dif-
ferent variables, e.g. contraceptive methods or initiation of
therapy in a different phase of the menstrual cycle, could
have inﬂuenced the effectiveness of the probiotic treatment,
but the limited number of enrolled patients did not permit
subgroup analysis.
It must be emphasized that the therapy, although not typi-
cally pharmacological but entirely probiotic, achieved a cure








Day 0 Day 7a Day 21b Day 0 Day 7 Day 21
Increased discharge 18 (2) 8 (1.5) 10 (1) 16 (2.5) 16 (2.5) 15 (2.5)
Vulvar discomfort 14 (2) 4 (1.5) 2 (1.5) 12 (2) 9 (2) 8 (2)
Malodour 17 (3) 6 (1.5) 5 (1) 16 (2.5) 14 (2) 14 (2.5)
ap <0.022 and bp <0.011 for comparison of each symptom at each time-point
between Lactobacillus-treated and placebo-treated groups.
Median score of clinical symptoms and signs of symptomatic patients is reported
in parenthesis. Range is from 0 (none) to 3 (high).
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rate in the lower range of typical pharmacological therapies,
which have cure rates from 60% to 85% 10–21 days after
the completion of treatment [13]. BV resolution has been
observed 2 weeks after treatment in 75% of non-pregnant
women treated with clindamycin vaginal cream [40]. In
asymptomatic pregnant women, Klebanoff et al. [41] found
two 2-g doses of metronidazole to be 60% effective in redu-
cing Nugent scores to <4 at 2–3.9 weeks after the start of
therapy.
It is important to note that the probiotic treatment was
very well tolerated and no side effects have been reported.
The absence of side effects is a great advantage of probiotic
treatment in comparison to antibiotic treatment. In fact, a
longer treatment regimen or repeated treatments could be
suggested for those women with continuing or recurring
clinical symptoms.
We observed spontaneous resolution of BV (score <7) in
19% of placebo-treated women and spontaneous reversion
to ‘normal vaginal ﬂora’ in 6% (score <4). Schwebke [42]
reported that, after administration of placebo vaginal gel to
30 asymptomatic non-pregnant women, 22% of the patients
had Gram stain scores <7 and 4% Gram stain scores <4
2 weeks after enrolment. Klebanoff et al. [41] observed
Gram stain scores <7 in 13% and <4 in 5% of placebo-trea-
ted women at 2–3.9 weeks after the start of therapy; both
of these results are similar to ours.
Different species of lactobacilli have been evaluated for
the treatment of BV. Lactobacillus acidophilus was used intra-
vaginally in a double-blind, placebo-controlled clinical trial.
Halle´n et al. [30] demonstrated that immediately after com-
pletion of a 6-day treatment, 57% of 28 patients were free
of BV, as compared to none of the 29 women in a placebo
group. Resolution of BV was maintained in 21% of Lactobacil-
lus-treated patients 20–40 days after the start of treatment.
The only property of the strain used in this study that may
be relevant for the treatment of BV was the production of
H2O2. Using well-characterized and well-selected strains,
Reid et al. [32] recently demonstrated that oral intake of Lac-
tobacillus rhamnosus GR-1 and Lactobacillus fermentum RC-14
resulted in a signiﬁcant increase in vaginal lactobacilli and a
signiﬁcant depletion in yeasts and coliforms for Lactobacillus-
treated healthy women, as compared with controls, during a
60-day treatment period. Two weeks after the end of a 1-
month course of oral treatment with different amounts of
the same strains, restoration from bacterial vaginosis micro-
ﬂora to a normal Lactobacillus-colonized microﬂora was
observed in four of nine (44%) asymptomatic women [31].
Intravaginal administration of these strains showed cure of
BV in signiﬁcantly more probiotic-treated subjects than
metronidazole-treated subjects [33]. Ten and 25 days after
the end of a 5-day treatment with lactobacilli or metronida-
zole vaginal gel, resolution of BV (Nugent score <7) was
achieved in 17 ⁄ 20 (85%) and 15 ⁄ 17 (88%), respectively, pro-
biotic-treated women, in comparison to 9 ⁄ 20 (45%) 9 ⁄ 18
(50%), respectively, of metronidazole-treated women.
The strains of lactobacilli present in the vaginal tablets
used in this study were carefully selected for properties
relating to mucosal colonization, i.e. their ability to adhere at
high levels to human epithelial cells [35] and to colonize the
human vagina [36]. The results of this study demonstrate
that 78% of women with an absence of, or very low amounts
of, lactobacilli at inclusion in the study had lactobacilli in vagi-
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FIG. 1. HPLC analysis of polyamines in vaginal samples of a patient
treated with the probiotic preparation. (a) Baseline (Nugent
score 7). (b) First follow-up (Nugent score 0). (c) Second follow-up
(Nugent score 3). HDA, hexamethylendiamine; Put, putrescine; Cad,
cadaverine.
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The observation that two women with intermediate vagi-
nal ﬂora and a high level of lactobacilli at inclusion in the
study recovered after treatment with lactobacilli is intriguing.
Although this aspect was not analysed in detail, it may be
suggested that endogenous lactobacilli are not able to coun-
teract BV-related microorganisms, whereas the strains pre-
sent in the vaginal tablets are.
An additional advantage observed with the Lactobacillus
preparation used in this study is the reduction of malodor-
ous vaginal discharge, which is the primary subjective symp-
tom and complaint of women affected with BV. Vaginal
malodour disappeared in most of the actively treated
patients, including non-BV-free women and, if persistent, it
was of lower intensity. This is conﬁrmed by the signiﬁcant
reduction in vaginal concentrations of polyamines observed
in the vaginal ﬂuid of women cured of BV after administra-
tion of Lactobacillus-containing vaginal tablets. Indeed, amines
produced by the overgrowing anaerobic microorganisms are
responsible for the vaginal malodour observed in BV-affected
women [11,12]. The effect on vaginal malodour could be
ascribed to the CD2 strain of L. brevis present in the vaginal
tablets. This strain produces high levels of the enzyme argi-
nine deiminase, which is able to downregulate polyamine
synthesis [43]. As the primary objective of BV treatment in
non-pregnant women is to alleviate symptoms, particularly
the ‘ﬁshy’ odour that is characteristic of vaginal discharges,
the probiotic preparation used in this trial could represent
an important step towards improving the efﬁcacy of bacter-
iotherapy for BV.
In conclusion, it is feasible to repopulate the vagina of
women having recurrent BV with the use of exogenous lac-
tobacilli. Carefully selected strains of lactobacilli can restore
a normal vaginal ﬂora and eliminate bacterial vaginosis. The
possibility of restoring a healthy vaginal microbiota is of great
importance, not only for the therapy of BV, but also as a
potential intervention to reduce the risk of acquiring HIV-1
infection and other sexually transmitted diseases [17].
Finally, vaginal probiotic administration could be suggested
in cases of recurrent bacterial vaginosis, to avoid repeated
use of antibiotics and as prophylaxis for dismicrobism with
depletion of lactobacilli in the female genital tract following
systemic antibiotic administration.
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